Crispr Genomic Cure Market

Crispr Genomic Cure Market, By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Other Diseases), By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy), By Delivery Method (In vivo (directly into the patient's body), Ex vivo (modification of cells outside the body before reintroduction)), By Application (Therapeutic Applications, Research Applications), By End-User (Hospitals and Clinics, Research Institutes, Biotechnology and Pharmaceutical Companies), By Regulatory Status (Approved Therapies, Investigational Therapies) Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification), By Market Segment (Pediatric Patients, Adult Patients), By Awareness and Support Organizations (CRISPR-Cas9 Genome Editing Therapeutics Society, Genetic Disease Advocacy Organizations, Cancer Research, Foundations, Rare Disease Foundations, Biotechnology and Pharmaceutical Associations), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

CRISPR is a unique technology for the targeted editing and regulation of genes that can be applied to a number of biological systems. Researchers use CRISPR to alter genes in plant, bacteria, and animal models. It is widely used in disease model studies and helps in understanding the genetic basis of disease for development of better therapeutics. The technology enables rapid, economical model generation through precise genome editing that accurately recapitulates the disease. It has also been put to use as experimental test to detect the novel coronavirus. CRISPR is a technology that can be used to edit genes and, as such, will likely change the world.

Market Dynamics:

Increasing prevalence of chronic disease, genetic disease, infectious diseases, neurological disease, blood disease, and metabolic disease, growing geriatric population, growing demand for safe and effective treatment or therapies, increasing funding for cell and gene therapies, frequent approvals for gene therapies, introduction of novel therapies, and increasing awareness among people about Crispr genomic cure are major factors expected to augment growth of the global Crispr genomic cure market during the forecast period.

For instance, in March 2021, Scientists at UC San Francisco, UC Berkeley, and UCLA received the U.S. Food and Drug Administration (FDA) approval to jointly launch an early phase, first-in-human clinical trial of a CRISPR gene correction therapy in patients with sickle cell disease using the patient’s own blood-forming stem cells. The therapy has the potential to transform sickle cell disease care by producing an accessible, curative treatment that is safer than the current therapy of stem cell transplant from a healthy bone marrow donor. Moreover, the therapy has the potential to prevent irreversible complications of the disease.

Key features of the study:

This report provides in-depth analysis of the global Crispr genomic cure market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.

It profiles key players in the global Crispr genomic cure market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.

Key companies covered as a part of this study include Merck KgaA, Takara Bio Inc., Lonza Group Ltd., Horizon Discovery Group plc, GenScript Biotech Corporation, Synthego Corporation, Precision Biosciences, Inc., Mammoth Biosciences, Caribou Biosciences, Inc., Beam Therapeutics Inc., Sangamo Therapeutics, Inc., Intellia Therapeutics, Inc., Editas Medicine, Inc., CRISPR Therapeutics AG, and Thermo Fisher Scientific Inc., among others.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.

The global Crispr genomic cure market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Crispr genomic cure market.

Detailed Segmentation:

Global Crispr Genomic Cure Market, By Disease Type:

Genetic Disorders

Cancer

Infectious Diseases

Neurological Disorders

Cardiovascular Disorders

Blood Disorders

Metabolic Disorders

Other Diseases

Global Crispr Genomic Cure Market, By Therapy Type:

Gene Editing

Gene Therapy

Cell Therapy

Immunotherapy

Global Crispr Genomic Cure Market, By Delivery Method:

In vivo (directly into the patient's body)

Ex vivo (modification of cells outside the body before reintroduction)

Global Crispr Genomic Cure Market, By Application:

Therapeutic Applications

Research Applications

Global Crispr Genomic Cure Market, By End User:

Hospitals and Clinics

Research Institutes

Biotechnology and Pharmaceutical Companies

Global Crispr Genomic Cure Market, By Regulatory Status:

Approved Therapies

Investigational Therapies

Global Crispr Genomic Cure Market, By Targeted Genetic Modification:

Single Gene Modification

Multiple Gene Modification

Genome-wide Modification

Global Crispr Genomic Cure Market, By Market Segment:

Pediatric Patients

Adult Patients

Global Crispr Genomic Cure Market, By Awareness and Support Organizations:

CRISPR-Cas9 Genome Editing Therapeutics Society

Genetic Disease Advocacy Organizations

Cancer Research Foundations

Rare Disease Foundations

Biotechnology and Pharmaceutical Associations

Global Crispr Genomic Cure Market, By Region:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Company Profiles:

Merck KgaA

Takara Bio Inc.

Lonza Group Ltd.

Horizon Discovery Group plc

GenScript Biotech Corporation

Synthego Corporation

Precision Biosciences, Inc.

Mammoth Biosciences

Caribou Biosciences, Inc.

Beam Therapeutics Inc.

Sangamo Therapeutics, Inc.

Intellia Therapeutics, Inc.

Editas Medicine, Inc.

CRISPR Therapeutics AG

Thermo Fisher Scientific Inc.